HomePatientsPublic Advisory RoundtableAwards ▶ Bruce C. Trapnell, MD
Bruce C. Trapnell, MD

Dr. Trapnell is the Francis R. Luther Endowed Chair and Professor of Medicine and Pediatrics at the University of Cincinnati and attending physician at Children's Hospital and University Hospital Medical Centers in Cincinnati, Ohio. He is Director of Translational Pulmonary Research and the Cincinnati Cystic Fibrosis Therapeutics Development Network Center and Assistant Director of the Adult Cystic Fibrosis Care Center.

A long time and ardent supporter of patient advocacy, Dr. Trapnell served on the Cystic Fibrosis Foundation's Research and Training Grant Review committee for 12 years, as the Scientific Director for the Alpha-1 Foundation from 2002 to 2006 and currently as the Scientific Director of the Pulmonary Alveolar Proteinosis Foundation. He organized and now chairs the Alpha-1 Foundation's Grants Advisory Committee and is a member of their Medical and Scientific Advisory Committee (MASAC). He founded and serves as Director of the Rare Lung Diseases Clinical Research Consortium, an international clinical research group with sites located in the United States, Canada, Japan and Australia that is dedicated clinical research on alpha-1 antitrypsin deficiency, pulmonary alveolar proteinosis, lymphangioleiomyomatosis, and hereditary pulmonary fibrosis. Dr. Trapnell also serves on the Steering Committees for the Cystic Fibrosis Therapeutics Development Network, and the Rare Diseases Clinical Research Network, and on Data Safety Monitoring Boards overseeing clinical trial safety for the Cystic Fibrosis Foundation and other organizations. He has conducted lung disease research since his initial training at the NIH and has been continuously funded by the NIH since 2001, shortly after his arrival in Cincinnati. He has published over 90 peer-reviewed scientific manuscripts, invited review articles and textbook chapters and has trained more than 16 post-doctoral fellows. Dr. Trapnell's research interests are focused to the pathogenesis and therapy of rare lung diseases and mechanisms by which GM-CSF regulates innate immunity and lung host defense.